Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

213
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
213
Fundamental Mathematical Principles in Pharmacokinetics: Mathematical Expressions and Units01:19

Fundamental Mathematical Principles in Pharmacokinetics: Mathematical Expressions and Units

1.5K
Mathematical principles play a crucial role in pharmacokinetics, providing a framework for understanding and quantifying drug distribution and elimination dynamics in the body. By utilizing mathematical expressions and units, pharmacologists can accurately characterize the behavior of drugs, optimize dosing regimens, and predict therapeutic outcomes.
One significant application of mathematics in pharmacokinetics is the characterization of drug distribution through the volume of distribution...
1.5K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

211
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
211
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

176
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
176
Fundamental Mathematical Principles in Pharmacokinetics: Calculus and Graphs01:21

Fundamental Mathematical Principles in Pharmacokinetics: Calculus and Graphs

3.1K
The fundamental mathematical principles, such as calculus and graphs, play crucial roles in analyzing drug movement and determining pharmacokinetic parameters. Differential calculus examines rates of change and helps to determine the dissolution rate of drugs in biofluids, as well as how drug concentrations change over time. For instance, it can help calculate the rate of elimination of a drug from the body based on its concentration-time profile.
On the other hand, integral calculus focuses on...
3.1K
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

228
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
228

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AI is Excellent at the Discovery and Identification of Unrecognized Scientific Knowledge but There Is No Evidence That AI Can Create New Scientific Knowledge.

Journal of clinical pharmacology·2026
Same author

Net Influx Rather Than Directional Rates: Re-evaluating Transporter Characterization In Vivo and In Vitro for Renal and Hepatic Clearance.

The AAPS journal·2025
Same author

Is there a possibility that P-glycoprotein reduces reproductive toxicity in males but breast cancer resistance protein does not?

Clinical and translational science·2024
Same author

Commentary: Pharmacokinetic Theory Must Consider Published Experimental Data.

Drug metabolism and disposition: the biological fate of chemicals·2024
Same author

An Explanation of Why Dose-Corrected Area Under the Curve for Alternate Administration Routes Can Be Greater than for Intravenous Dosing.

The AAPS journal·2024
Same author

The Uses and Advantages of Kirchhoff's Laws vs. Differential Equations in Pharmacology, Pharmacokinetics, and (Even) Chemistry.

The AAPS journal·2023

Related Experiment Video

Updated: Jan 29, 2026

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.6K

Mathematical Modeling in Drug Metabolism and Pharmacokinetics: Correct In Vitro, Not Always Valid In Vivo.

Leslie Z Benet1, Jasleen K Sodhi1

  • 1Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California San Francisco, San Francisco, CA 94143, USA.

Pharmaceuticals (Basel, Switzerland)
|January 28, 2026
PubMed
Summary

This study introduces a new pharmacokinetic framework using adapted Kirchhoff's Laws, simplifying clearance and rate constant derivations. It highlights limitations of differential equations for in vivo drug disposition, offering a model-independent approach for clinical data interpretation.

Keywords:
Kirchhoff’s lawsbioavailabilitydifferential equationsdrug metabolismhepatic clearancemean residence timespharmacokineticsrenal clearance

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

9.1K
Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure
08:25

Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure

Published on: June 5, 2020

7.3K

Related Experiment Videos

Last Updated: Jan 29, 2026

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.6K
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

9.1K
Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure
08:25

Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure

Published on: June 5, 2020

7.3K

Area of Science:

  • Pharmacokinetics
  • Systems Biology
  • Chemical Kinetics

Background:

  • Traditional pharmacokinetic models rely on differential equations, which may falter in vivo due to varying distribution volumes.
  • Extending amount-based equations to concentration-based clearance can be unreliable in dynamic physiological systems.

Purpose of the Study:

  • To present an alternative, mechanistically agnostic framework for pharmacokinetic relationships using adapted Kirchhoff's Laws.
  • To identify scenarios where traditional differential equation approaches may fail in vivo.
  • To offer a simpler, model-independent method for interpreting clinical pharmacokinetic data.

Main Methods:

  • Adapted Kirchhoff's Laws to model pharmacokinetic systems as networks of rate-defining processes.
  • Derived clearance and rate constant equations by summing parallel and in-series processes.
  • Incorporated organ blood flow, transporter effects, and delivery kinetics.
  • Compared results with differential equation models and the Extended Clearance Concept (ECC).
  • Applied the framework to a hypothetical drug (KL25A) case study.

Main Results:

  • Reproduced standard pharmacokinetic analyses without specific organ assumptions.
  • Developed model-independent hepatic and renal clearance equations.
  • Highlighted inconsistencies in differential equation models for slow absorption or differing volumes of distribution.
  • Demonstrated the framework's utility in interpreting complex pharmacokinetic scenarios.

Conclusions:

  • Linear pharmacokinetic relationships can be derived using parallel and in-series process summation, bypassing differential equations.
  • Differential equation methods may inaccurately estimate in vivo clearance and bioavailability.
  • The adapted Kirchhoff framework provides a robust, model-independent basis for clinical pharmacokinetic data analysis.